Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that while nanoparticle-loaded dissolving microneedles have considerable promise for enhancing transdermal drug delivery, progress is delayed by insufficient understanding of their in vivo behavior, which the authors emphasize as crucial for advancing clinical applications.

This review examines various methods for purifying extracellular vesicles loaded with drugs, highlighting their principles, benefits, and drawbacks, and stresses the importance of standardized guidelines to enhance the reproducibility of EV-based drug delivery research.

This review discusses the roles of key epithelial-mesenchymal transition factors and potential therapeutic opportunities involving cancer metabolic pathways, reporting no new clinical results.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

This case report suggests that anidulafungin may be associated with hair loss, highlighting the need for physicians to monitor this potential adverse effect.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This study suggests that itraconazole may significantly improve therapy for aspergillosis, with 12 out of 15 evaluable patients responding to the treatment.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

In this case study of a 64-year-old woman with kerion celsi caused by Microsporum canis, treatment with the oral antifungal fosravuconazole resulted in symptom resolution without scarring or side effects over 12 weeks, suggesting its potential effectiveness for various dermatomycoses.

This study found that the protein Fetuin A, when injected into fetal wounds that typically heal without scarring, caused scar formation and increased collagen production in fibroblasts in an animal model.

This case report details the successful use of oral itraconazole in treating a giant tufted angioma with hair loss that developed during pregnancy, leading to significant symptom relief and hair regrowth after discontinuation of the medication.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

In this study, researchers developed a novel topical gel combining minoxidil and JAK inhibitor tofacitinib, which effectively enhanced hair follicle growth and reduced local inflammation in mice with alopecia areata, suggesting a new approach for treating this condition.

This study found that Ishophloroglucin A from brown seaweed may treat androgenic alopecia by inhibiting 5α-reductase and promoting hair growth-related factors in human dermal papilla cells.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

This case report describes a 52-year-old woman with erythema annulare centrifugum after using topical luliconazole and oral itraconazole, suggesting a drug-induced reaction confirmed by a positive rechallenge test.

This study developed a silk fibroin/poly(vinyl alcohol) microneedle loaded with α-aminoxyacetate and HfO₂ nanoparticles for vitiligo treatment, which protected against ROS damage and modulated immune responses, leading to improved melanogenesis and skin repigmentation.

This case report describes a 20-year-old female with favus caused by T. schöenleinii, which initially improved with antifungal treatment but recurred due to poor adherence, underscoring favus as an ongoing health issue in Turkey.

This review discusses the developments in antifungal treatments for dermatophyte infections since 2008, reporting no new oral agents but introducing newer topical options like efinaconazole and tavaborole.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.